Summary:
Click image to enlargeNational Research Institute is enrolling participants in a clinical research study for migraine headaches. Insurance is not needed to participate in this study.
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants with Episodic Migraine.
Qualified Participants Must:
• Participant must be 18 to 75 years of age
•
1 yr history of migraines
•
Have 4-14 migraines headache days and at least 2 migraine attacks per month on average within the past 3 months
•
BMI: Less than 40
Qualified Participants May Receive:
If you qualify to participate in this study, you will receive free:
- If qualify and decide to participate compensation of $100 for the study visits you complete.
- Study-related medication at no cost,
- Study-related medical exams at no cost